BIB- BIOTECHNOLOGY PRO SHARES ETF ON THE RISE AS COVID-19 SECOND WAVE INBOUND

 In Uncategorized

The BIB is a Nasdaq biotechnology Proshares ETF.

The ETF has shown high volume being pushed in to the industry over the last few months as COVID-19 search for a vaccine & cure is on, backed up by governments and biotech companies being driven to push R&D time frame to max ability and to be able to fight this thing head-on next year with a cure or a vaccine.
Needless to say the instrument we should all be holding now is the BIB as it is comprised from the very best of all biotech companies and instrument performance is leveraged by 2.
In a CFD format it is leveraged by 20 or 30, depending on the broker aside from the ETF neutral leverage.
Recent Posts

Leave a Comment

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt